Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 176 In stock
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
ATR [12]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM 1.8 μM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTiVG4zNjVizszN NITTRWsyNTRiZB?= NX;jZpFYTE2VTx?= M4PPWIVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv MmTNNlU1QTB|OEO=
H1703 NGC4VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe4OGIzNjVizszN MoTBNU01KGR? NYTpUY9zTE2VTx?= NGPacG5mdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIITy[YF1dWWwdDD3bZRpKHSjbX;4bYZmdg>? NYjqeHBvOjV2OUCzPFM>
HUVECs NYi0U482S3m2b4TvfIlkcXS7IFHzd4F6 NET6eXkyODBibl2= NELqVFMzPCCq NGHJToVifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? Mn;hNlU1PTBzOE[=
APRE-19 NHLRbnFCeG:ydH;zbZMhSXO|YYm= NX22[3VzPSEQvF2= MljuNlQhcA>? NYf4[G9R[WKxbHnzbIV{KE[OWj3t[YRq[XSnZDDwdo8ue3W{dnn2ZYww[W62aT3hdI9xfG:|aYOgZYN1cX[rdIm= MVqyOVMzQTZzNx?=
MDA-MB-231 NVLV[5FQSXCxcITvd4l{KEG|c3H5 MnLjNeKh|ryPwrC= NXrCSoZyPDhiaB?= M1LHd2ROW09? NUe2bHFW\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKHS{ZXH0[YQhf2m2aDCyOUDPxE1ib3[gSlEhd3JiRkKgxsA> NWTrS|VlOjV|MEC5N|I>
MCF7 NHvBS4lHfW6ldHnvckBCe3OjeR?= M3LJfVExOCCwTR?= MVmyOEBp M3\BPIVtcW2rbnH0[ZMhTTJvaX7keYNm\CCDUlWtUJVkKGGldHn2bZR6 MX2yOVE4OjV3Nx?=
HT-29  M4r2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4SzN|EvPcLiwsXN NY\QUm5IQTZiaB?= MVnk[YNz\WG|ZYOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHnubIljcXSnZDDifUBMYU6D NVPoOFFZOjVyMUKxNlM>
MO59K  NFfiT2pEgXSxdH;4bYNqfHliQYPzZZk> M2WzWFXDqM7:TR?= MofnO{Bl MoLCSG1UVw>? M1PWO4VvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= M3nzSlI1QTV|NU[x
MO59J NH:wWm5EgXSxdH;4bYNqfHliQYPzZZk> M4rJUVXDqM7:TR?= M4S3fFch\A>? M4r0TWROW09? M2ruSYVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= MVmyOFk2OzV4MR?=
MO59K  NVHRfFh7SXCxcITvd4l{KEG|c3H5 MYWxNEDPxE1? MXGyOEBp MU\EUXNQ MoPCbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv M{LiWVI1QTV|NU[x
MO59J NVn4R5dHSXCxcITvd4l{KEG|c3H5 NITlNFgyOCEQvF2= NULMSJhTOjRiaB?= Mn7oSG1UVw>? MVjpcoNz\WG|ZYOgeIhmKESVQjDs[ZZmdCCrbnT1Z4VlKGK7IHX0c5Bwe2mmZTDvdkBkcXOybHH0bY4> MkfzNlQ6PTN3NkG=
HepG2 NF\aT5JHfW6ldHnvckBCe3OjeR?= M3ryU|ExOCCwTR?= MnO0NE42KGh? NH71Wm1FVVOR MlXTZoxw[2u|IF3BMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> NYTOWG5xOjR6NkOzOVA>
A549  NXf0b5ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Pfoc{KML3TdMg NX3QTIx[OiCq M1;OVpN2eHC{ZYPz[ZMheGWvZYTy[Zhm\C2rbnT1Z4VlKEGtdDDhcoQhT1ONM98yJIFkfGm4YYTpc44tKFNvcHjhd4Uh[XK{ZYP0MEBk\WyuIHHwc5B1d3OrczDhcoQh[2G|cHHz[U0{KGGldHn2ZZRqd25? NYK0T5k3OjR6NEe4OlM>
A549  NVX2V3FMTnWwY4Tpc44hSXO|YYm= NHzEfnQyOMLizsztxsA> NUj4SpJFOTZiaB?= Mn\pSG1UVw>? MoTvcY9lfWyjdHXzJJRp\SCLQW[gdoVxdGmlYYTpc44h[W6mIHPheZNmeyC{ZYTlcpRqd25ib3[gUnAhcW5idHjlJI52[2yndYOu MViyOFgxOjFzMR?=
SK-N-LO MmnOSpVv[3Srb36gRZN{[Xl? NXSyOHNnOTByIH7N NI\qRWIxNjViaB?= M4DTOIRm[3KnYYPld{B1cGVic4TpcZVt[W62IHXm[oVkfHNib3[gcY9zeGirbnWgc44hSWu2IIDoc5NxcG:{eXzheIlwdg>? NFjBR4UzPDZ3NE[wOi=>
HL-60 NIXVclZHfW6ldHnvckBCe3OjeR?= MUSwMlHDqM7:TR?= M4ixUFczKGh? NUXaT3dD[myxY3vzJIRie2G2aX7pZk1qdmS3Y3XkJINmdGxiZHnm[oVz\W62aXH0bY9v MnroNlQ3ODd{N{O=
HepG2  M37sUGZ2dmO2aX;uJGF{e2G7 MXKyNFAhdk1? MW[wMlUhcA>? MVvheJRmdnWjdHXzJGZwgE9icHjvd5Bpd3K7bHH0bY9v Mn21NlQ2OzVzOUK=
H520 NWXJc2M4TnWwY4Tpc44hSXO|YYm= NX;LdnhnOTEEoN88US=> M3fUSlEhcA>? MnfaSG1UVw>? NFzXRZFl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> NEjrc5ozPDR2N{mzOS=>
H1975 NXv1[oppTnWwY4Tpc44hSXO|YYm= MXGxNOKh|ryP M{HaZ|EhcA>? M4LPc2ROW09? Mk[4[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz NWPp[lhXOjR2NEe5N|U>
MG-63 M3LWOGFxd3C2b4Ppd{BCe3OjeR?= MVixNEDDvU1? Mmm4NVIhcA>? MljP[Y5p[W6lZYOgSHAucW6mdXPl[EBieG:ydH;zbZM> MXeyOFM2QDNyMR?=
5637 M3S3UGFxd3C2b4Ppd{BCe3OjeR?= NV7Bc3FkOTEEoN88US=> NFHrbXc1OCCvaX6= Ml7wdoV3\XK|ZYOgdFIyX0GIMTDlfJBz\XO|aX;uMEBETEtiZYjwdoV{e2mxbjygZY5lKGOnbHygbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KG[3Y3;p[IFv NHvEPWszPDN|M{i2PC=>
HEK-293 MlLKSpVv[3Srb36gRZN{[Xl? NFvEbpYyPTCwTR?= MoXINVYhcA>? M2LheWROW09? M4j5SYRm[3KnYYPld{BEWlRiYXP0bZZqfHl? NEPpVHgzPDN{NEO2Oi=>
SW480  NYDIRYUyTnWwY4Tpc44hSXO|YYm= M2\JbFE2OG6P M4PCdlIxKGh? NGi3Z41FVVOR NV\VOJFPemWmdXPld{Bk\WyudXzhdkBi[2O3bYXsZZRqd25ib3[g{tIu[2G2ZX7pci=> M2rxflI1OzJ2M{[2
HepG2 M{nNU2Z2dmO2aX;uJGF{e2G7 NYTPVnNiOTByIH7N MY[yOEBp NXnRPYp2[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= M2e5dFI1Ojl5NUGw
HCT 116  M{DmcGZ2dmO2aX;uJGF{e2G7 MYSxNFAhdk1? NVfXbVhoOjRiaB?= MXfheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? NEXD[40zPDJ7N{WxNC=>
BEL/FU NWL1TZZRTnWwY4Tpc44hSXO|YYm= NFjPWGIyKG2P NXTHUpU5OjRiaB?= MWfk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> M1H1c|I1OjN{MEm5
Huh7  NV7Ke|lxTnWwY4Tpc44hSXO|YYm= NV3wVIlmO8LizszN M1GzUFEhcA>? NVXDdG5CemWmdXPld{B1cGVidnnyeZMh\W62comgbY51dyC2aHWgZ4VtdHN? NV6wOlJzOjRzOESxPVY>
A-375 MXfBdI9xfG:|aYOgRZN{[Xl? NWDXcFJmPC96IN88US=> MX:yOEBp M1rNcIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MVOyOFEyOzF5Mx?=
A-375-TS  MmfqRZBweHSxc3nzJGF{e2G7 M3LCOFQwQCEQvF2= NUDFfGo5OjRiaB?= MUPlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MYmyOFEyOzF5Mx?=
Mel-HO M4rnNGFxd3C2b4Ppd{BCe3OjeR?= NHvW[|k1NzhizszN M2XrOVI1KGh? NFOySJVmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NYjTTpBHOjRzMUOxO|M>
Mel-HO-TS MlzsRZBweHSxc3nzJGF{e2G7 M1jPZVQwQCEQvF2= M2O5XFI1KGh? NV2zWFl[\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MV[yOFEyOzF5Mx?=
MeWo NXPPS|hnSXCxcITvd4l{KEG|c3H5 M3W0R|QwQCEQvF2= M4LZXFI1KGh? NX7qdZJs\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NWi4UIlSOjRzMUOxO|M>
Mel-2a M4L4N2Fxd3C2b4Ppd{BCe3OjeR?= Ml;NOE85KM7:TR?= Mn\uNlQhcA>? M1HSdIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= MY[yOFEyOzF5Mx?=
MDA-MB-231 MkCySpVv[3Srb36gRZN{[Xl? NYDGO5FlOOLCk{SwNEBvVQ>? Mn\OOEBp M3XpeZN2eHC{ZYPz[ZMhSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4PXZ|IzQTB4MkW5
MDA-MB-231 NH21SGdHfW6ldHnvckBCe3OjeR?= NF32WGU1ODBibl2= M2q2TVQhcA>? Ml3v[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX7UeWcxOjJ7ME[yOVk>
Jurkat NE\JNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXywMlI2NTFwMkWg{txO MlnwNlQwPDhiaB?= NX\lW5R1TE2VTx?= MoH0bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? MmLqNVk4PTdzOEW=
Namalwa NH\0PGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK4VoNSOC5{NT2xMlI2KM7:TR?= MoDONlQwPDhiaB?= M4DtUWROW09? M{S5eYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ NIjXOGsyQTd3N{G4OS=>
Jurkat M{L6V2Fxd3C2b4Ppd{BCe3OjeR?= MlnaNE4zPS1zLkK1JO69VQ>? Ml;HNlQwPDhiaB?= NUK5NlRmTE2VTx?= MkLjbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy M3XvPFE6PzV5MUi1
Namalwa NUfrNWhPSXCxcITvd4l{KEG|c3H5 M2T2flAvOjVvMT6yOUDPxE1? MoLKNlQwPDhiaB?= Ml6wSG1UVw>? NV3wNphKcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz NInoNIMyQTd3N{G4OS=>
K562 MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLmNlQhcA>? NEnM[ZpKSzVyPUK1xtExNjF2IH7N NVHPbFU4OTl4NkKzOlE>
SW1990 MkHCSpVv[3Srb36gRZN{[Xl? NFu0O5AxNjBzLUGg{txO NIHvVHMyKGh? MWnpcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> MUGxPVQ3QTB{MB?=
RT112  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXLNVDDqM7:TR?= NG\a[IwzPCCq NUjtbHVwTE2VTx?= MlfK[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> Mk\SNVg4QDd6M{K=
MHG-U1 NHXF[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7FNVDDqM7:TR?= NXvZTWc6OjRiaB?= M1zs[GROW09? Mmr5[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> MlXZNVg4QDd6M{K=
SMMC-7721 NVnoNmFpSXCxcITvd4l{KEG|c3H5 MmP6NlAxyqCwTR?= M2jQUVI1KGh? M33C[Ilv[3KnYYPld{BEUFhvaX7keYNm\CCjcH;weI9{cXN? NUnM[pREOTd3NUexPVE>
SMMC-7721 MXjGeY5kfGmxbjDBd5NigQ>? MnXkNlAxyqCwTR?= MkDaNlQhcA>? NGX6cWZ2eC2{ZXf1cIF1\XNizsKxMFRIXDFiZYjwdoV{e2mxbh?= NEXkXoQyPzV3N{G5NS=>
HeLa M17QfWZ2dmO2aX;uJGF{e2G7 M{\lZVExOMLibl5CpC=> MkjuNUBp MWjhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= MnfsNVY5QTB7MUW=
MRC5VI NELWNJFHfW6ldHnvckBCe3OjeR?= NYHWdINQOTJwNTDtUS=> NXLX[IdJOC53IHi= NWDQb2hjTE2VTx?= MmnHZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NECyTVEyPjJ{N{O5OC=>
AT5BIVA M3nCUmZ2dmO2aX;uJGF{e2G7 NIHjflEyOi53IH3N NEXPOYoxNjViaB?= M1PRTmROW09? MmDRZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> MXKxOlIzPzN7NB?=
M059J MoPESpVv[3Srb36gRZN{[Xl? NHPyOIkyOi53IH3N M3q1clAvPSCq NIPjNlJFVVOR NXvCV29m[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? MV:xOlIzPzN7NB?=
HeLa M4fFVWZ2dmO2aX;uJGF{e2G7 MUWxNk42KG2P MWiwMlUhcA>? M{PwZ2ROW09? NF65PJFi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MmrRNVYzOjd|OUS=
N2a NF7oT5JCeG:ydH;zbZMhSXO|YYm= MXywMlEuOTBizszN M{j5SlIhcA>? NEHBNHZqdmS3Y3XzJIRm[3KnYYPl[EBk\WyuII\pZYJqdGm2eTDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= NWHTblBlOTV6NEK3Olc>
Jurkat  MnnQT4lv[XOnIFHzd4F6 MXnJR|UxKG:oIEK0JI5O M{DnWlE2PjZ2NUG5

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
5%DMSO+corn oil
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID